ストックスクリーナーアプリを入手
1.99
1.97%
-0.04
プレマーケット:
2.02
0.03
+1.51%
前日終値:
$2.03
開ける：
$2.03
24時間の取引高:
1.15M
Relative Volume:
1.02
時価総額：
$408.35M
収益：
$889.00K
当期純損益:
$-156.28M
株価収益率:
-3.7782
EPS:
-0.5267
ネットキャッシュフロー:
$-150.06M
1週間 パフォーマンス:
+5.29%
1か月 パフォーマンス:
+10.56%
6か月 パフォーマンス:
-11.56%
1年 パフォーマンス:
+212.30%
1日の値動き範囲:
$1.99
$2.206
1週間の範囲:
$1.87
$2.24
52週間の値動き範囲:
$0.5916
$7.13
Prokidney Corp Stock (PROK) Company Profile
Compare PROK vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.99 | 418.61M | 889.00K | -156.28M | -150.06M | -0.5267 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-30 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-30 | 開始されました | JP Morgan | Neutral |
| 2024-09-10 | 開始されました | Guggenheim | Buy |
| 2024-03-07 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-01-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-07-25 | 開始されました | BTIG Research | Buy |
| 2022-12-21 | 開始されました | Jefferies | Buy |
| 2022-11-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 開始されました | UBS | Buy |
| 2022-10-14 | 開始されました | Citigroup | Buy |
| 2022-09-23 | 開始されました | BofA Securities | Buy |
| 2022-09-02 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Prokidney Corp (PROK) 最新ニュース
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Value Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Value Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Growth Benchmark Index - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell 2000 Growth Benchmark - marketscreener.com
ProKidney Corp.(NasdaqCM: PROK) added to Russell Microcap Index - marketscreener.com
Price to earnings forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to earnings forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Price to sales forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to revenue forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Enterprise value to EBIT forward of ProKidney Corp. Class A – BMV:PROK - TradingView
Enterprise value to EBITDA forward of ProKidney Corp. – NASDAQ:PROK - TradingView
Price to sales forward of ProKidney Corp. Class A – BMV:PROK - TradingView
ProKidney Corp (PROK) Valuation: PE, PB & Fair Value Analysis - TradingKey
ProKidney Corp. Class A Actuals & Estimates (NASDAQ:PROK) - TradingView
ProKidney Corp. (PROK) Faces Selling Pressure Near Resistance – Key Levels in FocusDouble EMA - dars.gov.et
PROK Forecast — Price Target — Prediction for 2027 - TradingView
ProKidney (PROK) Study Update Summary - Quartr
ProKidney Corp (PROK) Institutional Confidence - TradingKey
ProKidney Corp (PROK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ProKidney Corp (PROK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ProKidney Corp (PROK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PROK Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
ProKidney Corp (PROK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path - Yahoo Finance
ProKidney Corp (PROK) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ProKidney Corp (PROK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ProKidney Corp (PROK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ProKidney (NASDAQ: PROK) legal chief converts paired units to Class A stock - Stock Titan
ProKidney Corp. (PROK) Q1 2026 Earnings: Narrow EPS Beat Amid Clinical ProgressOperating Margin Analysis - newsline.com
[Form 3] PROKIDNEY CORP. Initial Statement of Beneficial Ownership - Stock Titan
Identiv And Two Other Penny Stocks To Watch Closely - simplywall.st
PROK: Phase III cell therapy for advanced CKD targets dialysis delay, with pivotal data due in 2027 - TradingView
ProKidney appoints Kenneth Locke as chief technical officer - The Pharma Letter
ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout - The Business Journals
ProKidney expands executive management team with chief technical officer - Winston-Salem Journal
Prokidney Corp. Announces Appointment of Kenneth Locke as Chief Technical Officer - marketscreener.com
ProKidney names Kenneth Locke as chief technical officer By Investing.com - Investing.com Australia
ProKidney Corp. Appoints Kenneth Locke as Chief Technical Officer - geneonline.com
ProKidney names Kenneth Locke as chief technical officer - Investing.com
ProKidney Appoints Kenneth Locke as Chief Technical Officer - The Manila Times
ProKidney shareholders reaffirm board and auditor at 2026 meeting - The Globe and Mail
PROKIDNEY CORP. (PROK) director receives 135,000 stock options grant - Stock Titan
Director at PROKIDNEY CORP. (PROK) receives 135,000 stock options as compensation - Stock Titan
ProKidney (PROK) director receives 135,000 stock options grant as compensation - Stock Titan
ProKidney (PROK) director awarded 135K stock options as compensation - Stock Titan
ProKidney (NASDAQ: PROK) grants 135,000 stock options to director - Stock Titan
[Form 4] PROKIDNEY CORP. Insider Trading Activity - Stock Titan
PROKIDNEY (NASDAQ: PROK) director receives 135,000 stock options as equity award - Stock Titan
ProKidney (NASDAQ: PROK) 2026 meeting backs board nominees and EY - Stock Titan
ProKidney Corp. (PROK) Edges Higher Amid Continued Support: Potential for Breakout Above $1.94 ResistanceCombination Correction - The Legal Advocate
Prokidney Corp (PROK) 財務データ
収益
当期純利益
現金流量
EPS
Prokidney Corp (PROK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
0.05%
0.74%
大文字化:
|
ボリューム (24 時間):